SOPHARMA AD - Sales revenues for October 2023

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. Sales_Revenues_October_2023_espi.pdf Sales revenues for October 2023
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 197 / 2023

Date of issue: 2023-11-20

Short name of the issuer

SOPHARMA AD

Subject

Sales revenues for October 2023

Official market - legal basis

art. 56. 1. 2 of Act on Public Offering.

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, November 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that for the month of October 2023, the Company realized an increase in sales of 45% compared to the same month of the previous year, incl. 53% increase in domestic sales and 42% increase in export sales.
For the ten months from the beginning of 2023, sales increased by a total of 18%, incl. a 5% increase in domestic sales and a 27% increase in export sales.

Annexes

File Description

Sales_Revenues_October_2023_espi.pdfSales_Revenues_October_2023_espi.pdf Sales revenues for October 2023

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2023-11-20 Ognian Donev Executive Director